More on 01801
News
- Innovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2α-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal
- Ollin Biosciences Announces Upcoming Presentations of OLN324 Data in Diabetic Macular Edema and Wet Age-Related Macular Degeneration at the American Society of Retina Specialists (ASRS) 44th Annual Sc
- Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China
- Ollin Biosciences raises $330M Series B to fund eye disease trials
- Innovent's Partner Ollin Biosciences Announces Oversubscribed $330 Million Series B Financing to Advance Global Phase 3 Development of IBI324 (OLN324) in DME and Wet AMD; Studies Commencing in Second
- Ollin Biosciences raises $330M Series B for eye disease drug trials
- Ollin Biosciences Announces Oversubscribed $330 Million Series B Financing to Advance Global Phase 3 Development of OLN324 in DME and Wet AMD; Studies Commencing in Second Half of 2026
- Innovent begins Phase 3 trial of tri-specific antibody for myeloma
- Innovent Biologics Announces First Patient Dosed in a Phase 3 Clinical Trial of IBI3003(GPRC5D/BCMA/CD3 Tri-specific Antibody) for the Treatment of Multiple Myeloma
- 2026 ADA | Innovent Presents Multiple Clinical and Preclinical Results of Next-Generation Obesity & Metabolic Pipeline
Entities mentioned with 01801
- FDA | View Related Stories »
- S1 | View Related Stories »
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- PDUFA | View Related Stories »
- IPO | View Related Stories »
- AdCom | View Related Stories »
- JPMorgan | View Related Stories »
- Show More...
